EZZ

Ezz Life Science Holdings

Consumer Discretionary Distribution & Retail

EZZ Life Science Holdings Limited is a genomic life science company focused on enhancing human health through innovative products and cutting-edge genomic research. The company leverages a dynamic omnichannel strategy to distribute premium health and wellness products across Australia, New Zealand, China, and other global markets. EZZ is committed to empowering consumers with science-backed soluti...

genomic research

consumer health

e-commerce

innovation

Shorted

short percentage0.00%

reported shorts4

shares on issue47.043M

About

website

ezzlife.com.au

industry

Consumer Discretionary Distribution & Retail

address

104 Derby Street, SILVERWATER, NSW, AUSTRALIA, 2128

Connect

Key Metrics

market cap

$76.21M

p/e ratio10.80

eps$0.15

dividend yield247.00%

More Consumer Discretionary Distribution & Retail Stocks

Other shorted stocks in this sector

View all stocks in this industry

Short Position Trends

Track bearish sentiment and short interest over time

Historical Price Data

View stock price movements, volume, and trading patterns

Industry & Focus

genomic research

consumer health

e-commerce

innovation

ASX

Company Overview

AI-generated company summary

Company History

EZZ Life Science Holdings was founded with a mission to improve quality of life and human health through genomic research. Over the years, the company has expanded its product offerings and market reach, establishing a strong presence in Australia, New Zealand, and China. EZZ has achieved significant milestones in product innovation and distribution, positioning itself as a leader in the genomic life sciences sector.

Competitive Advantages

EZZ Life Science Holdings benefits from its strong foundation in genomic research, allowing it to develop innovative health products. The company's omnichannel distribution strategy enhances its market reach and consumer engagement. Additionally, EZZ's focus on science-backed solutions provides a unique value proposition in the health and wellness industry.

Risk Factors

•Regulatory changes in health product markets
•Dependence on key markets like China
•Potential competition from larger pharmaceutical companies

Recent Developments

Last 6 months

In the past six months, EZZ Life Science Holdings has continued to expand its product line and strengthen its distribution channels, particularly in the Asia-Pacific region. The company has also focused on enhancing its e-commerce capabilities to better serve its global customer base.

Key People

Leadership team at Ezz Life Science Holdings

James Hudson

CEO

James Hudson is the CEO and Director of Corporate Affairs at EZZ Life Science Holdings, overseeing media relations, investor relations, and public affairs. He has a background in corporate affairs and marketing, previously working with Alibaba Group and the Australia China Business Council.

Jay Stephenson

CFO

Jay Stephenson is the Chief Financial Officer at EZZ Life Science Holdings, with over 35 years of experience in business development, finance, and corporate governance. He has held roles as Director, CFO, and Company Secretary across various industries.

Financial Reports

29 reports available

Quarterly Activities/Appendix 4C Cashflow Report

Quarterly ReportOct 30, 2025via asx_announcements

Appendix 4E - Preliminary Final Report

Annual ResultsAug 29, 2025via asx_announcements

Annual Report to shareholders

Annual ReportAug 29, 2025via asx_announcements

Quarterly Activities / Appendix 4C Cashflow Report

Quarterly ReportJul 29, 2025via asx_announcements

Quarterly Activities/Appendix 4C Cashflow Report

Quarterly ReportApr 24, 2025via asx_announcements

Half Yearly Report and Accounts

Half Year ResultsFeb 26, 2025via asx_announcements

Notice of FY25 Half Year Results and Investor Webinar

Half Year ResultsFeb 7, 2025via asx_announcements

Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly ReportJan 23, 2025via asx_announcements

Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly ReportOct 24, 2024via asx_announcements

Annual Report to shareholders

Annual ReportOct 15, 2024via asx_announcements

Showing 10 of 29 reports